Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer
Wataru Fukuokaya(Jikei University School of Medicine), Akihiro Hirakawa(Tokyo Medical and Dental University), Fumihiko Urabe(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Alberto Briganti(Vita-Salute San Raffaele University), Shahrokh F Shariat(Cornell University), Paweł Rajwa(University College London), Keiichiro Mori(Jikei University School of Medicine), Nobuaki Matsubara(National Cancer Center Hospital East)
Cited by 3
Related Papers
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282